1. Demystifying the Science of Monoclonal Antibodies in Migraine

2. Introduction

3. Pathophysiology of Migraine: Hypothesis of Site of Action of Migraine Medications

4. Anti-CGRP Medications and Binding Sites

5. Evolution of Therapeutic mAbs

6. Novel Approach for Migraine Prophylaxis: Specific Antibodies

7. Fully human vs humanized therapeutic mAbs for dyslipidemia

8. CGRP in the Central Nervous System

9. CGRP, Migraine Therapy, and the BBB

10. Anti-CGRP mAb Erenumab in Patients With Stable Angina: Peripheral Action of CGRP

11. Tolerability of Anti-CGRP mAbs Similar to Placebo

12. Trigeminal Ganglion as a Key Regulator in Headache

13. mAbs vs Small Molecules

14. Antibody Binding to Receptor Complex: Target Specificity

15. Differences Between mAbs and Traditional Preventive Migraine Medications

16. Patients With More Than 50% Reduction in Migraine Days With mAbs

17. A Look to the Future: Questions to Be Addressed in Real-Life Practice and Concluding Remarks

18. Abbreviations